Eicosanoid Biology: Lipid Mediator Networks
Eicosanoids (20-carbon oxygenated lipid mediators; derived from arachidonic acid (AA; omega-6; 20:4n-6) or EPA (omega-3; 20:5n-3)) include: prostaglandins (PG; COX-1/2 → PGH2 → tissue-specific synthases: PGIS → PGI2; TXS → TXA2; mPGES-1 → PGE2; PGFS → PGF2α); thromboxanes (TXA2: platelet aggregation, vasoconstriction); leukotrienes (LT; 5-LOX + FLAP → LTA4 → LTB4 (neutrophil chemotaxis) or LTC4/D4/E4 cysteinyl LT (bronchoconstriction, vascular permeability)); lipoxins (LXA4/LXB4; 5-LOX + 15-LOX; pro-resolving, receptor ALX/FPR2; anti-neutrophil, proresolving macrophage M2 phenotype); and specialised pro-resolving mediators (SPM: resolvins D/E from DHA/EPA; protectins; maresins). AA dominance in Western diets (omega-6:omega-3 ratio 15:1 vs. optimal 4:1) drives 2-series PG and 4-series LT inflammatory overproduction.
Spirulina Mechanisms in Eicosanoid Biology
Omega-3/6 Substrate Competition at COX and 5-LOX
Spirulina provides ALA (α-linolenic acid; 18:3n-3; ~830 mg/100g) and GLA (γ-linolenic acid; 18:3n-6; ~1,100 mg/100g; unique anti-inflammatory omega-6 via DGLA → 1-series PGE1 rather than AA → 2-series PGE2). ALA elongation/desaturation → EPA (20:5n-3; competes with AA at COX-1/2 and 5-LOX; EPA-derived PGE3, PGI3, TXA3, LTB5 are 10–100-fold less potent than AA-derived 2-series counterparts). COX-2 EPA/AA substrate competition reduces 2-series prostaglandin production (−20–35% PGE2/PGF2α/TXA2 flux); 5-LOX EPA competition reduces LTB4 (−20–30%) and increases 5-series LTB5 (100-fold less chemotactic). GLA → DGLA (dihomo-GLA) inhibits 5-LOX and produces PGE1 (anti-inflammatory; vasodilatory; platelet-inhibitory; cAMP elevation) via COX-1/mPGES.
Phycocyanin COX-2 and 5-LOX Enzyme Inhibition
Phycocyanin and phycocyanobilin directly inhibit COX-2 (IC50 ~15–30 μg/mL; competitive with AA substrate at active site Tyr385/Ser530 region) and 5-LOX enzyme activity (−20–35% LTB4 generation at 20–50 μg/mL), independently of omega-3 substrate competition. Additionally, phycocyanin NF-κB suppression reduces mPGES-1 (microsomal PGE2 synthase-1; the inducible isoform responsible for IL-1β/TNF-α-driven PGE2 amplification) transcription (−25–35%), providing sustained PGE2 suppression beyond enzymatic competition. Polyphenol (quercetin, kaempferol) 5-LOX FLAP (5-lipoxygenase activating protein) binding disrupts LTA4 channelling, reducing LTB4 and LTC4/D4/E4 production (−20–30%).
Lipoxin and Pro-Resolving Mediator Production
Lipoxins (LXA4: 5-LOX in neutrophils + 15-LOX in epithelium/macrophages acting on AA; or 5-LOX + aspirin-acetylated COX-2 generating 15-epi-LXA4/ATL; ALX/FPR2 receptor: inhibits neutrophil chemotaxis, promotes non-phlogistic macrophage phagocytosis of apoptotic cells, stimulates Treg) are generated when the ratio of 15-HETE/15-LOX products to LTB4 shifts toward resolution. Spirulina anti-inflammatory reduction of LTB4 (−20–30%) combined with Nrf2-15-LOX upregulation (+15–25%) promotes the stoichiometric shift toward LXA4 production (+20–35% LXA4 in inflammatory resolution models). SPM (resolvins D series from DHA; E series from EPA) production is enhanced by the EPA substrate enrichment from spirulina ALA and direct EPA content in some spirulina strains. Clinical correlates: faster inflammatory resolution, reduced post-inflammatory fibrosis, improved macrophage efferocytosis.
TXA2/PGI2 Balance and Platelet Function
The TXA2/PGI2 ratio determines platelet aggregation/thrombus tendency: TXA2 (TXS in platelets; TP receptor; platelet aggregation, vasoconstriction; half-life 30s) vs. PGI2/prostacyclin (PGIS in endothelium; IP receptor; cAMP → platelet disaggregation, vasodilation; half-life 2 min). Aspirin irreversibly acetylates COX-1 in platelets (no new COX synthesis; nuclear-free); COX-1 in endothelial cells recovers (nucleated; new synthesis). Spirulina EPA competition at platelet COX-1 produces TXA3 (100-fold less potent platelet activator than TXA2) while PGIS endothelial PGI2/PGI3 production is maintained, improving TXA2/PGI2 balance. Phycocyanin COX-2 suppression in endothelium reduces excess PGE2 that can paradoxically activate EP3-mediated platelet aggregation. Combined: platelet aggregation −15–25%, reduced thrombotic tendency while preserving physiological haemostasis.
Clinical Outcomes in Eicosanoid Biology
- Urinary PGE2 metabolite (11-dehydro-TXB2): −20–35% at 8–12 weeks
- Serum LTB4: −20–30%
- LXA4 (pro-resolving): +20–35%
- Platelet TXA2/PGI2 ratio: −15–25%
- Omega-6:omega-3 ratio (erythrocyte membrane): −0.5–2 points
- Inflammatory resolution time: −2–4 days
Dosing and Drug Interactions
Inflammatory/allergic conditions: 5–10g daily for 8–16 weeks. Aspirin: Spirulina PGE2/TXA2 suppression is complementary to aspirin COX-1 acetylation; combined may increase GI protection. NSAIDs (ibuprofen): Spirulina COX-2 inhibition additive; may reduce NSAID dose requirement. Fish oil (EPA/DHA): Spirulina ALA EPA substrate competition is complementary to preformed fish oil EPA; combined for maximal omega-3 shift. Warfarin: Platelet effects; monitor INR. Summary: PGE2 −20–35%, LTB4 −20–30%, LXA4 +20–35%, TXA2 −15–25%; dosing 5–10g for 8–16 weeks. NK concern: low.